Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11736626 | 0.99 | MAPT (0.76) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL10743621 | 0.89 | SIRT6 (0.74) | MAPTALDH1A1L3MBTL1SIRT6MAPK1 | |
| SCHEMBL341354 | 0.87 | MAPT (1.00) | MAPTALDH1A1HPGDCYP2C19LMNA | |
| SCHEMBL27249081 | 0.85 | LMNA (0.64) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL40110 | 0.85 | HPGD (0.62) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL20509684 | 0.85 | SIRT6 (0.81) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL25493925 | 0.84 | HPGD (0.61) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL3763530 | 0.84 | LMNA (0.62) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL44878 | 0.83 | SIRT6 (0.79) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL27957504 | 0.81 | MAPT (0.58) | MAPTALDH1A1HPGDCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| US-4053470-A | BACTERICIDES, ANTIBIOTICS | PARKE, DAVIS & COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-3954734-A | PENICILLIN AND CEPHALOSPORIN TYPE | PARKE, DAVIS & COMPANY | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | MAPT 4760/4885ALDH1A1 1258/4885HPGD 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.